When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
Quibim made huge strides in AI-powered diagnosis thanks to EU H2020
Taking part in the EU’s H2020 initiative translated into huge strides in disease detection and diagnosis by QUIBIM, by enabling the development of tools powered by artificial intelligence (AI) that allow to extract patterns from medical images and significantly improve human performance.
The program, which came to a term on June 30th, culminated in Quibim Precision® significantly expanding its network of customers and collaborators and an improved international brand awareness. More recently the Chest X-Ray Classification tool, another solution in the Quibim Precision® suite, also received CE clearance.
“We are very happy we’ve completed the program in time and line with all our objectives, allowing us to add one more stepping stone to the development of AI-boosted healthcare,” Quibim CEO Angel Alberich Bayarri said.
Quibim, a high-tech SME based in Valencia, Spain, received a €1.25M grant from the European Union’s Horizon 2020 research and innovation program in 2017, to help advance its machine learning and image processing algorithms to extract imaging biomarkers from images generated on CT, MRI, X-ray, US, DXA and PET scans.
With the EU’s support, the Spanish company could finalize the development, validation and automation of new imaging biomarkers in the areas of brain, lung and oncology, as well as achieve the integration of the new computing performance and data visualization frameworks for the QUIBIM platform.
Thanks to the automated analysis of imaging biomarkers, results are ready just within minutes with the best accuracy and reproducibility, through a medically certified, cost-effective and user-oriented solution, which is available to any physician using image-based diagnosis.
“QUIBIM allows physicians to make more accurate diagnosis by providing additional information extracted from the analysis of acquired imaging studies. Our technology uses algorithms that scout the image and extracts features as imaging biomarkers that can be compared to normative information in our database, based on patterns that are not easily visible to the human eye. The algorithms combine both AI data-driven techniques and model-driven approaches. As such, our products help to reduce costs of medical testing and misdiagnosis, especially from specialists,” Alberich said.
Quibim actively started in 2015 as a spinoff company of La Fe Hospital in Valencia, to help specialists including radiologists and pathologists make the most of AI in their everyday practice, by providing a one-stop-shop solution using imaging biomarkers and powerful algorithms.
More than 60 hospitals worldwide are currently working with Quibim tools, most of which have received CE marks and/or are FDA pending. The company has notably developed the new teaching platform of the European School of Radiology and has supplied its Quibim Precision® image analysis platform to the AI Precision Health Institute at the University of Hawai‘i Cancer Center in Honolulu.
Quibim has received €3.5m funding ever since its creation and has offices in Spain and the U.S. The company forecasts to generate revenues above €36 million and 150 direct jobs by 2023.
Autor: Melisande Rouger, 30 June 2019.